Glioblastoma Multiformerelapsed [CYT997 (IV) + carboplatin]
Study Design: single-arm, open-label
Primary Endpoints: safety and tolerability, progression-free survival at 6 months
Secondary Endpoints: objective response rate, overall survival, effect of pharmacodynamic markers of vascular disruption and tumor apoptosis, pharmacokinetic analysis
# Patients: 35 (enrollment ongoing)
Trial Location: Australia
Lead Sponsor: YM BioSciences Australia
|
|
|
|
|
Advanced Solid Tumors[CYT997 (oral) monotherapy]
Study Design: accelerated dose-escalation (oral administration)
Primary Endpoints: dose-limiting toxicities, maximum tolerated dose
Secondary Endpoints: pharmacokinetics, toxicities and tolerability, recommended dose, preliminary evaluation of anti-tumor and anti-vascular activity
# Patients: 21
Trial Location: Australia
Lead Sponsor: YM BioSciences Australia
|
|
|
|
|
Advanced Solid Tumorsrelapsed [CYT997 (IV) monotherapy]
Study Design: dose-escalation (intravenous administration)
Primary Endpoints: dose-limiting toxicities, maximum tolerated dose
Secondary Endpoints: pharmacokinetics, toxicities and tolerability, recommended dose, preliminary evaluation of anti-tumor and anti-vascular activity
# Patients: 31
Trial Location: Australia
Lead Sponsor: YM BioSciences Australia
|
|
|
|
|
